We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chronically Low Level of a Certain Biomarker Appears to Foreshadow Development of Type II Diabetes

By LabMedica International staff writers
Posted on 29 Jan 2014
An enzyme involved in regulation of mitochondrial energy metabolism has been linked to the development of type II diabetes, one of the consequences of aging.

Investigators at the Institut de Recherches Cliniques (Montreal, QC, Canada) worked with a strain of mice that had been genetically engineered to lack the gene that encodes the protein PGC-1alpha (peroxisome proliferator-activated receptor-gamma coactivator-1alpha) in certain muscle tissues. More...


PGC-1alpha is a regulator of mitochondrial biogenesis and function that controls the genes involved in energy metabolism. This protein interacts with the nuclear receptor PPAR-gamma, which permits its interaction with multiple transcription factors. PGC-1alpha provides a direct link between external physiological stimuli and the regulation of mitochondrial biogenesis, and is a major factor that regulates muscle fiber type determination. Endurance exercise has been shown to activate the PGC-1alpha gene in human skeletal muscle. This protein may be also involved in controlling blood pressure, regulating cellular cholesterol homoeostasis, and the development of obesity.

The investigators reared muscle-specific PGC-1alpha knockout mice and wild-type littermate controls for two years. Genetic signatures of skeletal muscle (microarray and mRNA expression) and metabolic profiles (glucose homeostasis, mitochondrial metabolism, body composition, lipids, and indirect calorimetry) were compared at three, 12, and 24 months of age.

Results reported in the November 26, 2013, online edition of the journal American Journal of Physiology – Endocrinology and Metabolism showed that microarray and gene set enrichment analysis highlighted decreased function of the electron transport chain as characteristic of both aging muscle and loss of PGC-1alpha expression. Despite significant reductions in oxidative gene expression and succinate dehydrogenase activity, young mice lacking PGC-1alpha in muscle had lower fasting glucose and insulin. Consistent with loss of oxidative capacity during aging, PGC-1alpha and PGC-1beta expression were reduced in aged wild-type mouse muscle. Indeed, the combination of age and loss of muscle PGC-1alpha expression impaired glucose tolerance and led to increased fat mass, insulin resistance, and inflammatory markers in white adipose and liver tissues. Therefore, loss of PGC-1alpha expression and decreased mitochondrial oxidative capacity contributed to the worsening glucose tolerance and chronic systemic inflammation associated with aging.

“My team and I studied PGC-1alpha, a protein responsible for regulating the production of energy in cells,” said senior author Dr. Jennifer Estall, director of the molecular mechanisms of diabetes research unit at the Institut de Recherches Cliniques. “Surprisingly, we found that young mice lacking this protein in their muscle tissue appeared healthier, as they had lower blood sugar levels before and after meals. So, at first, we thought having less of this protein was actually better. However, as they aged, the mice lacking the PGC-1alpha protein developed significant glucose intolerance and insulin resistance, which are hallmarks of type II diabetes. As a result, we discovered that chronically low levels of this protein in muscle may contribute to the development of diabetes later in life. Our study also suggests that low levels of PGC-1alpha in muscle could be a promising new way of predicting increased risk of type II diabetes at a young age, and drugs to increase the levels of this protein may help prevent or delay the progression of the disease.”

Related Links:

Institut de Recherches Cliniques



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.